全文获取类型
收费全文 | 234694篇 |
免费 | 15299篇 |
国内免费 | 988篇 |
专业分类
耳鼻咽喉 | 2523篇 |
儿科学 | 5989篇 |
妇产科学 | 4415篇 |
基础医学 | 29298篇 |
口腔科学 | 4319篇 |
临床医学 | 24053篇 |
内科学 | 49554篇 |
皮肤病学 | 3234篇 |
神经病学 | 23653篇 |
特种医学 | 10110篇 |
外国民族医学 | 13篇 |
外科学 | 37007篇 |
综合类 | 2536篇 |
现状与发展 | 1篇 |
一般理论 | 177篇 |
预防医学 | 16524篇 |
眼科学 | 5529篇 |
药学 | 15479篇 |
1篇 | |
中国医学 | 319篇 |
肿瘤学 | 16247篇 |
出版年
2023年 | 1335篇 |
2022年 | 2189篇 |
2021年 | 5331篇 |
2020年 | 3044篇 |
2019年 | 5052篇 |
2018年 | 6048篇 |
2017年 | 4442篇 |
2016年 | 4850篇 |
2015年 | 5732篇 |
2014年 | 8349篇 |
2013年 | 11243篇 |
2012年 | 17276篇 |
2011年 | 18011篇 |
2010年 | 10068篇 |
2009年 | 9309篇 |
2008年 | 15862篇 |
2007年 | 16654篇 |
2006年 | 16198篇 |
2005年 | 16052篇 |
2004年 | 15104篇 |
2003年 | 13784篇 |
2002年 | 13182篇 |
2001年 | 1926篇 |
2000年 | 1428篇 |
1999年 | 2001篇 |
1998年 | 2783篇 |
1997年 | 2212篇 |
1996年 | 1922篇 |
1995年 | 1761篇 |
1994年 | 1528篇 |
1993年 | 1492篇 |
1992年 | 978篇 |
1991年 | 923篇 |
1990年 | 782篇 |
1989年 | 745篇 |
1988年 | 676篇 |
1987年 | 612篇 |
1986年 | 635篇 |
1985年 | 678篇 |
1984年 | 908篇 |
1983年 | 786篇 |
1982年 | 1033篇 |
1981年 | 964篇 |
1980年 | 835篇 |
1979年 | 464篇 |
1978年 | 514篇 |
1977年 | 446篇 |
1976年 | 419篇 |
1975年 | 314篇 |
1974年 | 310篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
891.
Anthony P. Khalifah Ramsey R. Hachem Murali M. Chakinala Roger D. Yusen Aviva Aloush G. Alexander Patterson Thalachallour Mohanakumar Elbert P. Trulock Michael J. Walter 《American journal of transplantation》2005,5(8):2022-2030
Bronchiolitis obliterans syndrome (BOS) is a major cause of lung allograft dysfunction. Although previous studies have identified mild to severe rejection (grade>or=A2) as a risk factor for BOS, the role of minimal rejection (grade A1) remains unclear. To determine if A1 rejection by itself is a risk factor for BOS, we performed a retrospective cohort study on 228 adult lung transplant recipients over a 7-year period. Cohorts were defined by their most severe rejection episode (none, A1 only, and >or=A2) and analyzed for the subsequent development and progression of BOS using univariate and multivariate time-dependent Cox regression analysis. In the univariate model, the occurrence of isolated minimal rejection was a risk factor for all stages of BOS. Similarly, multivariate models that included HLA mismatch, cytomegalovirus pneumonitis, community acquired viral infection, underlying disease and type of transplant demonstrated that A1 rejection was a distinct risk factor for BOS. Furthermore, the associated risk with A1 rejection was slightly greater than the risk from >or=A2 and treatment of A1 rejection decreased the risk for subsequent BOS stage 1. We conclude that minimal rejection is associated with an increased risk for BOS development and progression that is comparable to A2 rejection. 相似文献
892.
Maurizio Fava Michael E Thase Charles DeBattista Karl Doghramji Sanjay Arora Rod J Hughes 《Annals of clinical psychiatry》2007,19(3):153-159
BACKGROUND: Partial response, no response, or residual symptoms following antidepressant therapy is common in clinical psychiatry. This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue. METHODS: This retrospective analysis pooled the data of patients (18-65 yrs) who participated in two randomized, double-blind, placebo-controlled studies of modafinil (6-week, flexible-dose study of 100-400 mg/day or 8-week, fixed-dose study of 200 mg/day) plus SSRI therapy. Patients (n=348) met criteria for several residual symptoms (Epworth Sleepiness Scale [ESS] score>or=10; 17-item Hamilton Depression Scale [HAM-D] score between 4 and 25; and Fatigue Severity Scale [FSS] score>or=4). RESULTS: Compared to placebo, modafinil augmentation rapidly (within 1 week) and significantly improved overall clinical condition (Clinical Global Impression-Improvement), wakefulness (ESS), depressive symptoms (17-item HAM-D), and fatigue (FSS) (p<.01 for all). At final visit, patients receiving modafinil augmentation experienced statistically significant improvements in overall clinical condition, wakefulness, and depressive symptoms. Modafinil was well tolerated in combination with SSRI. CONCLUSIONS: Results of this pooled analysis provide further evidence suggesting that modafinil is an effective and well-tolerated augmentation therapy for partial responders to SSRI therapy, particularly when patients continue to experience fatigue and excessive sleepiness. 相似文献
893.
894.
Michael S Blaiss 《Allergy and asthma proceedings》2007,28(2):145-152
Allergic rhinitis (AR) is a major chronic inflammatory disease of the upper airways. AR is increasing in prevalence and causes negative effects on quality of life, impairs performance and productivity, and imposes a serious economic burden. More than 20% of the American population suffers from AR. Intranasal corticosteroids (INS) are an effective and safe first-line treatment for AR, with potent anti-inflammatory properties and a high therapeutic ratio. The systemic bioavailability of the majority of INS is relatively low; however, the pharmacokinetics of absorption, first-pass metabolism, volume of distribution, half-life, and clearance of INS varies considerably, depending on lipophilicity, receptor affinity, and lipid conjugation in the nasal tissue. The short-term (e.g., effect on linear lower-leg growth rate) and long-term (e.g., effect on height) systemic side effects of INS in patients with AR are determined by these important characteristics. AR is present in up to 75% of patients with asthma, and patients with AR are three times more likely to develop asthma compared with patients without AR. Therefore, the overall increased systemic steroid burden resulting from concomitant use of inhaled corticosteroids (ICS) and INS in adult and pediatric patients with comorbid AR and asthma warrants critical monitoring of systemic side effects. This review evaluates the overall safety of INS in AR and the importance of systemic safety considerations of INS, particularly when coadministered with ICS. 相似文献
895.
896.
Mechanoregulation of human articular chondrocyte aggrecan and type II collagen expression by intermittent hydrostatic pressure in vitro. 总被引:6,自引:0,他引:6
897.
898.
899.
Dorota Gabry's Annegret Dörfler Ala Yaromina Franziska Hessel Mechthild Krause Reinhard Oertel Prof. Dr. Michael Baumann 《Strahlentherapie und Onkologie》2008,184(1):48-53
PURPOSE: To evaluate the effect of lovastatin alone or combined with radiation on U87MG and FaDu cells in vitro and U87MG tumors in vivo. MATERIAL AND METHODS: Cell number, p21(WAF1) expression, apoptosis, reproductive cell death, and cell-cycle distribution were investigated after incubation of U87MG and FaDu cells in vitro. The effect of lovastatin (50 mg/kg/day) on tumor growth and on tumor growth delay after single-dose irradiation with 20 Gy was investigated using U87MG tumors in nude mice. RESULTS: Lovastatin dose dependently decreased cell number and proliferation of U87MG and FaDu cells. The proportion of cells in G0/G1 phase, apoptosis and p21 protein expression increased after lovastatin alone or combined with 4-Gy irradiation in both cell lines. Effects of lovastatin on cell cycle and cell number were more pronounced in U87MG compared to FaDu. No radiosensitization of clonogenic cells by lovastatin could be demonstrated in both cells lines, but the colony-forming ability after lovastatin alone was decreased in FaDu cells. In vivo, lovastatin decreased tumor volume over time but did not increase growth delay after irradiation of U87MG tumors with 20 Gy. CONCLUSION: The data support effects of lovastatin on proliferation, apoptosis and colony-forming ability in vitro and tumor volume in vivo. At the drug concentration achievable, lovastatin did not improve the effects of radiation on U87MG tumors in vivo. 相似文献
900.
Michael C. Cheung Eduardo A. Perez Manuel A. Molina Xiaoling Jin Juan C. Gutierrez Dido Franceschi Alan S. Livingstone Leonidas G. Koniaris 《Journal of gastrointestinal surgery》2008,12(4):731-738
Objective The objective of the study was to determine the outcomes for primary gastrointestinal melanomas (PGIM).
Material and methods The Surveillance, Epidemiology, and End Results database (1973–2004) was queried.
Results Overall, 659 cases of PGIM were identified. The annual incidence of PGIM was approximately 0.47 cases per million in 2000.
Overall median survival time was 17 months. Tumors were identified in the oral–nasopharynx (32.8%), anal canal (31.4%), rectum
(22.2%), esophagus (5.9%), stomach (2.7%), small bowel (2.3%), gallbladder (1.4%), and large bowel (0.9%). Univariate analysis
demonstrated age, tumor location, stage, surgery, and lymph node status were significant predictors of improved survival.
MST has not been reached for tumors located in the large bowel, while tumors located in the stomach demonstrated the shortest
median survival (5 months). Improvement in MST was observed for those patients undergoing surgical resection. The presence
of lymph node involvement conferred a poorer prognosis. Multivariate analysis of the cohort identified that location, advanced
tumor stage, failure to undertake surgical resection, positive lymph node status, and age were all independent predictors
of poorer outcome.
Conclusion PGIM occurs most often in the oral–nasopharynx and anal canal. Surgical extirpation is the only identifiable treatment modality
that significantly improves survival. 相似文献